Streetbeat News

Price Targets

PINS

HSBC analyst Mohammed Khallouf has initiated coverage on Pinterest (NYSE:PINS) with a Buy rating and a price target of $32.1.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:42 am

SNAP

HSBC analyst Mohammed Khallouf has initiated coverage on Snap (NYSE:SNAP) with a Reduce rating and a price target of $7.5.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:41 am

GD

Berenberg analyst Charlotte Keyworth maintains a Market Perform rating on General Dynamics (NYSE:GD) and raises the price target from $254 to $258.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:29 am

STVN

Stephens & Co. analyst Jacob Johnson has initiated coverage on Stevanato Gr (NYSE:STVN) with an Overweight rating and a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:25 am

GLBE

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Global E Online (NASDAQ:GLBE) and maintained a $54 price target.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:22 am

DV

Needham analyst Laura Martin has reiterated a 'Buy' rating on DoubleVerify Hldgs (NYSE:DV) and maintained a price target of $45.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:17 am

MA

V

Truist Securities analyst Andrew Jeffrey has maintained a Buy rating for Mastercard Inc (NYSE:MA) and raised the price target from $450 to $475. Jeffrey is bullish on Mastercard's ePayment growth and B2B potential, citing global card volume growth, recent share gains, and the company's strategy of leading with solutions that lift issuers' revenue growth. He also highlighted Mastercard's Value-Added Services (VAS) portfolio, which focuses on Fraud, Intelligence, and Data.

Portfolio Pulse from Anusuya Lahiri

September 25, 2023 | 8:02 pm

PHVS

Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ:PHVS) with an Outperform rating and a price target of $27. The analyst sees a 35% upside potential and highlights Pharvaris' strategy to develop oral therapeutic options for hereditary angioedema (HAE). The analyst's estimates are skewed toward PHVS416, an acute HAE therapy, with a projected launch by FY26 and FY30 revenue reaching $644 million. The clinical hold on the PHVS719 program is expected to be lifted, allowing for advancement to the prophylactic market.

Portfolio Pulse from Vandana Singh

September 25, 2023 | 7:47 pm

CFLT

Over the past 3 months, 6 analysts have published their opinion on Confluent (NASDAQ:CFLT) stock. The company has an average price target of $40.5, up 35.0% from the previous average price target of $30.00. The ratings include 3 bullish, 1 somewhat bullish, and 2 indifferent.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 7:01 pm

MORF

Stifel analyst Alex Thompson maintains a 'Hold' rating on Morphic Holding (NASDAQ:MORF) and has lowered the price target from $61 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 6:26 pm